Source: Annual Congress 2005 - Advancements in diffuse parenchymal lung disease
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
I. van der Lee, P. Zanen, J. C. Grutters, R. J. Snijder, J. M. van den Bosch (Nieuwegein, Netherlands). Diffusing capacity for nitric oxide and carbon monoxide in patients with diffuse parenchymal lung disease and pulmonary arterial hypertension. Eur Respir J 2005; 26: Suppl. 49, 1808

Member's Comments

No comment yet.

Related content which might interest you: Carbon monoxide diffusing capacity and the complexity of diagnosis in pulmonary arterial hypertension Source: Eur Respir J 2014; 43: 963-965 Year: 2014 Combined measurement of carbon monoxide and nitric oxide lung transfer does not improve the identification of pulmonary hypertension in systemic sclerosis Source: Eur Respir J, 50 (4) 1701008; 10.1183/13993003.01008-2017 Year: 2017 Diffusing capacity for nitric oxide and capillary blood volume in patients with idiopathic interstitial pneumonia Source: Annual Congress 2008 - Pulmonary mechanics and gas exchange Year: 2008 Exhaled nitric oxide in patients with idiopathic pulmonary fibrosis and pulmonary hypertension Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology? Year: 2008 Diffusing capacity of the lung for nitric oxide and carbon monoxide: Influence of alveolar volume Source: Annual Congress 2010 - Advances in lung function I Year: 2010 Diffusing capacity for carbon monoxide and mortality in patients with chronic thromboembolic pulmonary hypertension Source: Annual Congress 2012 - Pulmonary circulation: acute and chronic pulmonary embolism Year: 2012 Reference equations for pulmonary diffusing capacity of carbon monoxide and nitric oxide in adult Caucasians Source: Eur Respir J, 52 (1) 1500677; 10.1183/13993003.00677-2015 Year: 2018 Bronchial blood flow is normal in COPD patients and is positevily correlated with exhaled nitric oxide and the diffusion of carbon monoxide Source: Eur Respir J 2006; 28: Suppl. 50, 652s Year: 2006 Diffusing capacity for nitric oxide and carbon monoxide in lung transplant recipients Source: Annual Congress 2008 - Lung and bone marrow transplantation: miscellaneous Year: 2008 Exhaled nitric oxide in chronic obstructive pulmonary disease: relationship to pulmonary function Source: Eur Respir J 2001; 17: 934-938 Year: 2001 Lung diffusing capacity for nitric oxide and carbon monoxide: methodological issues and reproducibility in patients with cystic fibrosis Source: Eur Respir J 2007; 30: Suppl. 51, 325s Year: 2007 The diagnostic value of exhaled carbon monoxide and arterial carboxyhaemoglobin measurements in chronic obstructive pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 408s Year: 2006 Diffusing capacity for carbon monoxide (DLco) may predict appearance of pulmonary hypertension in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Fractional exhaled nitric oxide in patients with chronic obstructive pulmonary disease Source: International Congress 2019 – FeNO in airway diseases and asthma-COPD overlap identification Year: 2019 Pulmonary veno-occlusive disease Source: Eur Respir J 2009; 33: 189-200 Year: 2009 Nitric oxide and oxygen inhalation during exercise in patients with chronic obstructive lung disease (COPD) and secondary pulmonary hypertension (PH) Source: Eur Respir J 2001; 18: Suppl. 33, 83s Year: 2001 Exhaled carbon monoxide is decreased in interstitial lung diseases (ILD) Source: Eur Respir J 2001; 18: Suppl. 33, 195s Year: 2001 Exhaled carbon monoxide measurement in patients with interstitial lung diseases (ILD) Source: Annual Congress 2008 - Clinical aspects of interstitial lung disease Year: 2008 Response to hypoxia of pulmonary arteries in chronic obstructive pulmonary disease: an in vitro study Source: Eur Respir J 2002; 20: 332-338 Year: 2002 No effect of baseline diffusing capacity of lung for carbon monoxide on benefit of nintedanib Source: International Congress 2016 – IPF treatment II Year: 2016